Emeis Stock Exceeds Bollinger Bands After a 44% Year-Over-Year Increase

TP Icap Midcap Shifts to Buy with a Target of 17 Euros

This Tuesday, April 28, 2026, the broker TP Icap Midcap initiated a buy recommendation on Emeis, with a price target set at 17.00 euros. Relative to the current price of 14.93 euros, this target represents a potential increase of about 14%. This signal comes as the group announced the appointment of Jean-Marc Boursier as the new deputy CEO, effective from July 1st. The current deputy CEO will also continue his role as the group's CFO. This governance change is part of a context of remarkable annual performance for the stock, which has risen over 44% over the year. In the healthcare sector, the session is mixed: Sanofi is up 0.61% in session, while UCB is down 4.54%. In the United States, Eli Lilly dropped 1.77% and Johnson & Johnson 0.95% at the day's close. The next key event for Emeis is the Q1 2026 revenue report, expected on Wednesday, May 6.

Stock Crosses Upper Bollinger Band, a Signal to Watch

Technically, Emeis stock is now trading above the upper Bollinger band, located at 14.92 euros, which constitutes a potential overbought signal. This setup indicates a significant deviation from its 20-day moving average (13.64 euros) and suggests an unusual bullish tension. The RSI, at 55, remains in a neutral zone, without marked excess on either side. All moving averages also confirm the upward trend: the MM50 is positioned at 14.00 euros and the MM200 at 13.53 euros, both well below the current price. The nearest resistance is at 15.06 euros, a threshold whose crossing could open a new trading level. The CAC 40 is up 0.28% in session at 8,164.62 points, providing a generally supportive environment for French mid-caps this Tuesday.